Kufer; Peter

Patent Applications and Registrations

Patent applications and USPTO patent grants for Kufer; Peter.The latest application filed is for "binding molecules for bcma and cd3".

Company Profile

25.57.90

Kufer; Peter - Munich DE
Kufer; Peter - Moosburg N/A DE
KUFER; Peter - Moosburg an der Isar DE
Kufer; Peter - Muenchen DE
Kufer; Peter - D-85368 Moosburg DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Bispecific T cell engaging antibody constructs Grant 11,434,302 - Raum , et al. September 6, 2	2022-09-06
Binding Molecules For Bcma And Cd3 App 20220251243 - Kufer; Peter ; et al.	2022-08-11
BCMA and CD3 bispecific T cell engaging antibody constructs Grant 11,352,433 - Raum , et al. June 7, 2	2022-06-07
Means and Methods for Treating Tumorous Diseases App 20220088196 - Bauerle; Patrick ; et al.	2022-03-24
Method For Treating Glioblastoma Or Glioma With Anitbody Constructs Egfrviii And Cd3 App 20220064308 - Raum; Tobias ; et al.	2022-03-03
Binding Molecules For Bcma And Cd3 App 20220064336 - Kufer; Peter ; et al.	2022-03-03
Cross-species-specific Single Domain Bispecific Single Chain Antibody App 20220041736 - Kufer; Peter ; et al.	2022-02-10
Means and methods for the treament of B cell non-hodgkin lymphoma and B cell leukemia Grant 11,154,617 - Baeuerle , et al. October 26, 2	2021-10-26
Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3 Grant 11,155,629 - Raum , et al. October 26, 2	2021-10-26
Antibody Constructs For Dll3 And Cd3 App 20210309743 - Raum; Tobias ; et al.	2021-10-07
Prolonged Administration Of A Bispecific Antibody Construct Binding To Cd33 And Cd3 App 20210301017 - Nagorsen; Dirk ; et al.	2021-09-30
CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY App 20210277143 - KUFER; Peter ; et al.	2021-09-09
CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY App 20210269550 - KUFER; Peter ; et al.	2021-09-02
Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains Grant 11,084,876 - Kufer , et al. August 10, 2	2021-08-10
Risk-stratification of B-precursor acute lymphoblastic leukemia patients Grant 11,079,381 - Zugmaier , et al. August 3, 2	2021-08-03
Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia Grant 11,053,318 - Zugmaier , et al. July 6, 2	2021-07-06
Bispecific antibody constructs for CDH3 and CD3 Grant 11,028,171 - Weiss , et al. June 8, 2	2021-06-08
Cross-species-specific single domain bispecific single chain antibody Grant 10,981,998 - Kufer , et al. April 20, 2	2021-04-20
PSMA and CD3 Bispecific T Cell Engaging Antibody Constructs App 20210070878 - Raum; Tobias ; et al.	2021-03-11
Cross-species-specific Pscaxcd3, Cd19xcd3, C-metxcd3, Endosialinxcd3, Epcamxcd3, Igf-1rxcd3 Or Fapalphaxcd3 Bispecific Single Chain Antibody App 20200362039 - Kufer; Peter ; et al.	2020-11-19
Antibody Constructs For Dll3 And Cd3 App 20200332002 - Raum; Tobias ; et al.	2020-10-22
PSMA and CD3 bispecific T cell engaging antibody constructs Grant 10,781,264 - Raum , et al. Sept	2020-09-22
Binding molecules for BCMA and CD3 Grant 10,766,969 - Kufer , et al. Sep	2020-09-08
Binding molecules for BCMA and CD3 Grant 10,752,694 - Kufer , et al. A	2020-08-25
Antibody constructs for DLL3 and CD3 Grant 10,683,351 - Raum , et al.	2020-06-16
Dosage regimen for administering a CD19XCD3 bispecific antibody Grant 10,662,243 - Nagorsen , et al.	2020-05-26
Antibody Constructs For Egfrviii And Cd3 App 20200140558 - Raum; Tobias ; et al.	2020-05-07
Cross-species-specific Bispecific Binders App 20200095319 - Kufer; Peter ; et al.	2020-03-26
Antibody Constructs For Cdh19 And Cd3 App 20200071405 - Xiao; Shouhua ; et al.	2020-03-05
Bcma And Cd3 Bispecific T Cell Engaging Antibody Constructs App 20200048357 - Raum; Tobias ; et al.	2020-02-13
Single chain binding molecules comprising N-terminal ABP App 20200040099 - Kufer; Peter ; et al.	2020-02-06
Antibody constructs for EGFRVIII and CD3 Grant 10,519,241 - Raum , et al. Dec	2019-12-31
Antibody Constructs For Dll3 And Cd3 App 20190263907 - Raum; Tobias ; et al.	2019-08-29
Long Life Polypeptide Binding Molecules App 20190169295 - Kufer; Peter ; et al.	2019-06-06
CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY App 20190169310 - Kufer; Peter ; et al.	2019-06-06
BCMA and CD3 bispecific T cell engaging antibody constructs Grant 10,301,391 - Raum , et al.	2019-05-28
Antibody constructs for DLL3 and CD3 Grant 10,294,300 - Raum , et al.	2019-05-21
Administration Of A Bispecific Construct Binding To Cd33 And Cd3 For Use In A Method For The Treatment Of Myeloid Leukemia App 20190127465 - Zugmaier; Gerhard ; et al.	2019-05-02
Compositions Comprising Cross-species-specific Antibodies And Uses Thereof App 20190070290 - Kischel; Roman ; et al.	2019-03-07
Bispecific Single Chain Antibodies With Specificity For High Molecular Weight Target Antigens App 20190040133 - Kufer; Peter ; et al.	2019-02-07
Antibody Constructs For Cdh19 And Cd3 App 20190016805 - Xiao; Shouhua ; et al.	2019-01-17
Antibody constructs for CDH19 and CD3 Grant 10,059,766 - Xiao , et al. August 28, 2	2018-08-28
Bispecific single chain antibodies with specificity for high molecular weight target antigens Grant 10,047,159 - Kufer , et al. August 14, 2	2018-08-14
Pharmaceutical compositions with resistance to soluble CEA Grant 9,982,063 - Lutterbuse , et al. May 29, 2	2018-05-29
Bispecific Antibody Constructs For Cdh3 And Cd3 App 20180142021 - Weiss; Bertram ; et al.	2018-05-24
Antibody Constructs For CDH19 and CD3 App 20180002450 - Xiao; Shouhua ; et al.	2018-01-04
Optimized Cross-species Specific Bispecific Single Chain Antibody Contructs App 20170349668 - Rattel; Benno ; et al.	2017-12-07
Anti-Leukocyte Adhesion for the Mitigation of Potential Adverse Events Caused by CD3-Specific Binding Domains App 20170327581 - Kufer; Peter ; et al.	2017-11-16
Bispecific Single Chain Antibody Construct With Enhanced Tissue Distribution App 20170275373 - Kufer; Peter ; et al.	2017-09-28
Antibody constructs for CDH19 and CD3 Grant 9,765,157 - Xiao , et al. September 19, 2	2017-09-19
Bispecific T Cell Engaging Antibody Constructs App 20170218078 - Raum; Tobias ; et al.	2017-08-03
Bcma And Cd3 Bispecific T Cell Engaging Antibody Constructs App 20170218077 - Raum; Tobias ; et al.	2017-08-03
PSMA and CD3 Bispecific T Cell Engaging Antibody Constructs App 20170218079 - Raum; Tobias ; et al.	2017-08-03
Pharmaceutical compositions with resistance to soluble CEA Grant 9,695,250 - Lutterbuse , et al. July 4, 2	2017-07-04
Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains Grant 9,688,760 - Kufer , et al. June 27, 2	2017-06-27
Pharmaceutical Compositions With Resistance To Soluble Cea App 20170137538 - Lutterbuse; Ralf ; et al.	2017-05-18
Risk-stratification Of B-precursor Acute Lymphoblastic Leukemia Patients App 20170122947 - Zugmaier; Gerhard ; et al.	2017-05-04
Binding molecules for BCMA and CD3 Grant 9,598,500 - Kufer , et al. March 21, 2	2017-03-21
Cross-species-specific PSMAxCD3 bispecific single chain antibody Grant 9,587,036 - Kufer , et al. March 7, 2	2017-03-07
Antibody Constructs For Dll3 And Cd3 App 20170037130 - Raum; Tobias ; et al.	2017-02-09
Antibody Constructs For Egfrviii And Cd3 App 20170029512 - Raum; Tobias ; et al.	2017-02-02
Antibody Constructs For Msln And Cd3 App 20170029502 - Raum; Tobias ; et al.	2017-02-02
Antibody constructs for influenza M2 and CD3 Grant 9,505,849 - Kufer , et al. November 29, 2	2016-11-29
PPS for the prevention of potential adverse effects caused by CD3 specific binding domains Grant 9,486,475 - Kufer , et al. November 8, 2	2016-11-08
Bispecific Single Chain Antibodies With Specificity For High Molecular Weight Target Antigens App 20160264671 - Kufer; Peter ; et al.	2016-09-15
Method of Treating a Patient or Exempting a Patient From Further Treatment Subsequent to Tumor Removal App 20160208338 - Kufer; Peter	2016-07-21
Binding Molecules For Bcma And Cd3 App 20160176973 - Kufer; Peter ; et al.	2016-06-23
Cross-species-specific Bispecific Binders App 20160152707 - Kufer; Peter ; et al.	2016-06-02
Binding molecules for BCMA and CD3 Grant 9,340,621 - Kufer , et al. May 17, 2	2016-05-17
Single Chain Binding Molecules Comprising N-terminal Abp App 20160122436 - Kufer; Peter ; et al.	2016-05-05
Bispecific single chain antibodies with specificity for high molecular weight target antigens Grant 9,260,522 - Kufer , et al. February 16, 2	2016-02-16
Antibody Constructs For Influenza M2 And Cd3 App 20160039948 - Kufer; Peter ; et al.	2016-02-11
Antibody constructs for CDH19 and CD3 App 20160032019 - Xiao; Shouhua ; et al.	2016-02-04
Antibody Constructs For Cdh19 And Cd3 App 20150368343 - Xiao; Shouhua ; et al.	2015-12-24
Binding molecules for BCMA and CD3 Grant 9,150,664 - Kufer , et al. October 6, 2	2015-10-06
Dosage Regimen For Administering A Cd19xcd3 Bispecific Antibody App 20150071928 - Nagorsen; Dirk ; et al.	2015-03-12
Long Life Polypeptide Binding Molecules App 20150037334 - Kufer; Peter ; et al.	2015-02-05
Binding Molecules For Bcma And Cd3 App 20150023967 - Kufer; Peter ; et al.	2015-01-22
Pharmaceutical antibody compositions with resistance to soluble CEA Grant 8,901,278 - Rau , et al. December 2, 2	2014-12-02
Binding Molecules For Bcma And Cd3 App 20140348837 - Kufer; Peter ; et al.	2014-11-27
Antibody Constructs for CDH19 and CD3 App 20140322218 - Xiao; Shouhua ; et al.	2014-10-30
Dosage regimen for administering a CD19XCD3 bispecific antibody Grant 8,840,888 - Nagorsen , et al. September 23, 2	2014-09-23
PPS for the prevention of potential adverse effects caused by CD3 specific binding domains App 20140228316 - Kufer; Peter ; et al.	2014-08-14
Anti-Leukocyte Adhesion for the Mitigation of Potential Adverse Events caused by CD3-Specific Binding Domains App 20140227272 - Kufer; Peter ; et al.	2014-08-14
Pharmaceutical composition comprising a bispecific antibody for EpCAM Grant 8,790,645 - Kufer , et al. July 29, 2	2014-07-29
Human-anti-human cd3 binding molecules Grant 8,784,821 - Kufer , et al. July 22, 2	2014-07-22
Pharmaceutical Compositions With Resistance To Soluble Cea App 20130273050 - LUTTERBUSE; Ralf ; et al.	2013-10-17
Binding Molecules For Bcma And Cd3 App 20130156769 - Kufer; Peter ; et al.	2013-06-20
Binding Molecules For Bcma And Cd3 App 20130156770 - Kufer; Peter ; et al.	2013-06-20
Compositions Comprising Cross-species-specific Antibodies And Uses Thereof App 20130129729 - KISCHEL; Roman ; et al.	2013-05-23
CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY App 20130129730 - Kufer; Peter ; et al.	2013-05-23
Means And Methods For The Treament Of Tumorous Diseases App 20130095103 - Baeuerle; Patrick ; et al.	2013-04-18
Pharmaceutical compositions with resistance to soluble CEA Grant 8,394,926 - Lutterbuse , et al. March 12, 2	2013-03-12
Dosage Regimen For Administering A Cd19xcd3 Bispecific Antibody App 20120328618 - Nagorsen; Dirk ; et al.	2012-12-27
Cross-species-specific Bispecific Binders App 20120244162 - KUFER; Peter ; et al.	2012-09-27
DOSAGE REGIMEN FOR ADMINISTERING AN EpCAMxCD3 BISPECIFIC ANTIBODY App 20120244161 - Zugmeier; Gerhard ; et al.	2012-09-27
Composition comprising cross-species-specific antibodies and uses thereof Grant 8,236,308 - Kischel , et al. August 7, 2	2012-08-07
Pharmaceutical Antibody Compositions With Resistance To Soluble Cea App 20120121600 - RAU; Doris ; et al.	2012-05-17
CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY App 20120034228 - Kufer; Peter ; et al.	2012-02-09
Less immunogenic binding molecules Grant 8,101,722 - Kufer , et al. January 24, 2	2012-01-24
CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY App 20110293619 - Kufer; Peter ; et al.	2011-12-01
Cross-species-specific Single Domain Bispecific Single Chain Antibody App 20110275787 - Kufer; Peter ; et al.	2011-11-10
Bispecific Single Chain Antibodies With Specificity For High Molecular Weight Target Antigens App 20110262439 - Kufer; Peter ; et al.	2011-10-27
Pharmaceutical Composition Comprising A Bispecific Antibody For Epcam App 20110256137 - Kufer; Peter ; et al.	2011-10-20
Means and methods for the treatment of tumorous diseases Grant 8,007,796 - Baeuerle , et al. August 30, 2	2011-08-30
Pharmaceutical composition comprising a bispecific antibody for EpCAM Grant 7,919,089 - Kufer , et al. April 5, 2	2011-04-05
Cross-species-specific Bispecific Binders App 20100183615 - Kufer; Peter ; et al.	2010-07-22
Cross-species-specific Binding Domain App 20100150918 - Kufer; Peter ; et al.	2010-06-17
Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders Grant 7,635,472 - Kufer , et al. December 22, 2	2009-12-22
Antibodies that bind human 17-A1/EpCAM tumor antigen Grant 7,632,925 - Kufer , et al. December 15, 2	2009-12-15
Means And Methods For The Treatment Of Tumorous Diseases App 20090291072 - Baeuerle; Patrick ; et al.	2009-11-26
Composition Comprising Cross-Species-Sepecific Antibodies and uses Thereof App 20090252683 - Kischel; Roman ; et al.	2009-10-08
Domain-grafted Antibodies App 20090241202 - Kufer; Peter ; et al.	2009-09-24
Pharmaceutical Antibody Compositions With Resistance To Soluble Cea App 20090226444 - Rau; Doris ; et al.	2009-09-10
Pharmaceutical Compositions With Resistance To Soluble Cea App 20090226432 - Lutterbuse; Ralf ; et al.	2009-09-10
CD19xCD3 specific polypeptides and uses thereof Grant 7,575,923 - Dorken , et al. August 18, 2	2009-08-18
Antibodies that bind human 17-A1/EpCAM tumor antigen App 20090081191 - Kufer; Peter ; et al.	2009-03-26
Real-time RT-PCR for the sensitive detection of multiple MAGE gene transcripts Grant 7,491,814 - Kufer , et al. February 17, 2	2009-02-17
Bispecific Antibodies App 20080305105 - Kufer; Peter ; et al.	2008-12-11
Method of identifying binding site domains that retain the capacity of binding to an epitope Grant 7,435,549 - Kufer , et al. October 14, 2	2008-10-14
Less Immunogenic Binding Molecules App 20080213256 - Kufer; Peter ; et al.	2008-09-04
EphA2 BiTE molecules and uses thereof App 20080044413 - Hammond; Scott A. ; et al.	2008-02-21
Bispecific antibodies Grant 7,235,641 - Kufer , et al. June 26, 2	2007-06-26
Human antibodies that bind human 17-A1/EpCAM tumor antigen Grant 7,227,002 - Kufer , et al. June 5, 2	2007-06-05
Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders App 20070123479 - Kufer; Peter ; et al.	2007-05-31
Pharmaceutical composition comprising a bispecific antibody for epcam App 20070081993 - Kufer; Peter ; et al.	2007-04-12
CD 19.times.CD3 specific polypeptides and uses thereof Grant 7,112,324 - Dorken , et al. September 26, 2	2006-09-26
Novel CD19xCD3 specific polypeptides and uses thereof App 20060193852 - Dorken; Bernd ; et al.	2006-08-31
Novel real-time rt-pcr for the sensitive detection of multiple mage gene transcripts App 20060147928 - Kufer; Peter ; et al.	2006-07-06
Bispecific antibodies App 20050136050 - Kufer, Peter ; et al.	2005-06-23
Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex App 20040038339 - Kufer, Peter ; et al.	2004-02-26
Antibodies against plasma cells App 20030180799 - Muller- Hermelink, Hans Konrad ; et al.	2003-09-25
Novel method for the production of anti-human antigen receptors and uses thereof App 20030148463 - Kufer, Peter ; et al.	2003-08-07
Primers and methods for the detection of disseminated tumor cells Grant 6,475,727 - Kufer , et al. November 5, 2	2002-11-05

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.